Lenacapavir HIV Prevention Injection Expands Access Across 14 Latin American Countries
Lenacapavir HIV prevention is becoming more accessible across 14 Latin American countries through a new PAHO procurement pathway. The twice-yearly injectable PrEP option may help people who struggle with daily tablets, privacy concerns or adherence, while still requiring proper HIV testing, clinical eligibility review and national programme approval.